Gilead Sciences, Inc. (GILD) Earnings Blaze a Star-Studded Future

Page 1 of 2

The global HIV market supports a large and lucrative business environment. With more than $13 billion in antiretroviral drug sales in 2011 — to just the United States and Europe’s five-largest markets alone — companies in this space can drum up substantial revenues by catering to the HIV patient population.

There may be no more successful company in this sphere than Gilead Sciences, Inc. (NASDAQ:GILD), however, which has established its foundation on blockbuster HIV drugs and emerged as a biotech power. Gilead’s been good to shareholders recently, with the stock up more than 18% over the last three months — but with earnings on tap, could the company keep up its momentum?

Gilead Sciences, Inc. (NASDAQ:GILD)Revenue soars, earnings beat
Revenue’s been roaring higher lately for Gilead, and analysts expected a strong showing from the fourth quarter. Investors were eager to see how the company’s latest drug, Stribild, would fare after launching in just August of last year, particularly as the company looks to diversify beyond HIV therapies as it expands its reach across the biotech sphere into hepatitis-C drugs, oncology, and more.

Fortunately, there’s no need for shareholders to fret, as Gilead scored yet another win. The company’s earnings surged yet again, with adjusted earnings per share coming in at $0.50 — up $0.01 from a year ago and beating analyst expectations by a full $0.03.

Sales also soared, as Gilead reported revenue of $2.59 billion for the fourth quarter, up 18% year-over-year. That number also smashed projections, which expected only $2.43 billion in revenue for the quarter. Things aren’t all rosy in sales, however: Gilead announced that between $80 million to $100 million of its sales came through wholesalers stocking up in the company’s drugs ahead of scheduled price increases for 2013. Company executive vice president of commercial affairs Kevin Young pointed out how such trends were beyond Gilead’s control, saying, “We cannot predict whether these purchaser activities will be repeated in 2013.”

Gilead’s already been hiking prices on its HIV drugs over 2012, a move that boosted revenue and also greatly irked the AIDS Healthcare Foundation. The AHF complained about the price hikes on Monday in light of Gilead’s raise of HIV therapy Atripla’s price in 2012, along with its announcement of Stribild as the most expensive drug on the market in September. Still, the results have worked well for investors, and if price hikes can keep fueling the company’s revenues, I doubt Wall Street — or Gilead’s management — will complain.

The numbers were good, and shares of Gilead responded positively in after-hours trading. In the aftermath of earnings, how should you view the future of this company?

A starstruck future for Gilead
Firstly, Gilead’s still shining brightly in an HIV market that’s continuing to rise. Blockbuster Atripla is cruising right along with 6% sales growth in the U.S. during the fourth quarter and 5% growth in Europe. That’s less than Gilead was recording through the first nine months of the year, but it didn’t hurt Atripla’s 11% sales growth throughout 2012. With full-year sales now eclipsing $3.5 billion, it’s been a good run for Atripla — but Gilead could soon face some serious pressure here, as the patent for a component of the drug, Sustiva, expires this year.

However, Stribild marks the future of Gilead’s HIV preeminence. Stribild combines four drugs into one medication and has already been shown to work as effectively as Atripla. The drug isn’t selling much now, with just $40 million in revenue in the fourth quarter after its launch last year, but analysts have already pegged sales expectations for Stribild in the billions. All signs point to this as Gilead’s future blockbuster and the true successor to Atripla.

Page 1 of 2
blog comments powered by Disqus
Insider Monkey Headlines
Insider Monkey Small Cap Strategy
Insider Monkey Small Cap Strategy

Insider Monkey beat the market by 52 percentage points in 24 months Click to see monthly returns in table format!

Lists

The 10 Countries with the Highest Suicide Rates

The 10 Most Technologically Advanced Countries in the World

The 10 Safest Countries in the World to Live in Peace

The 10 Top Selling Smartphones in the World 2014

The 12 Biggest Shopping Centers in the World

The 10 Friendliest Countries in the World

Qihoo 360 Technology Co Ltd (QIHU), Actavis plc (ACT), Yahoo! Inc. (YHOO) Among 20 Long Ideas from Sohn Canada

The 10 Laziest Countries in the World

The 10 Most Polluted Countries in the World

The 10 Most Dangerous Cities in America 2014

The Top 10 Gold Producing Countries in the World

The 10 Tallest Buildings in the World

The 10 Richest Stand Up Comedians in the World

The 10 Fattest Countries in the World

The 5 Best Summer Jobs for Teens

The 10 Most Religious Countries in the World Keeping the Faith

The 10 Most Educated Countries in the World

The 10 Most Popular Cell Phones in the World

The 10 Drunkest Countries in the World

The 10 Most Expensive Private Schools in the World

The 10 Smallest Countries in the World

Walking Dead Season 5 Spoilers You’ll Wish You Didn’t Know

The 10 Poorest Countries in the World

The 10 Greenest Countries in the World

The Top 10 Countries with the Highest Population in the World

The 10 Most Visited Countries in the World

The Top 10 Star Wars Characters in the Iconic Series

The 10 Most Expensive Android Phones in the World

5 Reasons Why The Illuminati Is Real and a Threat to Society

The 6 Scariest Halloween Costumes Ever Screamed At

The 4 Biggest Hedge Fund Managers in the World Today

The 15 Most Densely Populated Countries in the World

The 10 Biggest Tea Drinking Countries in the World

Top 6 Ways to Improve Your Checkout Process and Close Sales

The 5 Most Profitable Online Businesses You Can Start Today

The 20 Most Profitable Hospitals in the US

The 5 Most Profitable Home Businesses to Start

The 7 Teams that Will Win the Stanley Cup in 2015

The Top 10 Most Expensive Digital Cameras to Snap Stunning Shots With

The 10 Highest Quality Fast Food Restaurants In America Today

The 8 Best Halloween Decorating Ideas to Spook Up Your House

10 Marvel Women that Should Get a Movie Right Now

The 20 Best Remixes of Popular Songs that Will Make You Forget the Originals

7 Most Expensive Cities in the World

5 Least Expensive Cities in the World

10 Celebrities Who Believe In Scientology

10 High Margin Food Products to Build a Business Around

The 10 Most Expensive Clothing Stores in the United States to Get Decked Out At

The 5 Biggest Kickstarter Scams That Swindled Backers’ Donations

The 10 Most Expensive Boarding Schools In the World

Subscribe

Enter your email:

Delivered by FeedBurner

X

Thanks! An email with instructions is sent to !

Your email already exists in our database. Click here to go to your subscriptions

Insider Monkey returned 47.6% in its first year! Wondering How?

Download a complete edition of our newsletter for free!